Topic: hormone replacement therapy
AbbVie is in court facing the first of 4,100 defendants in a class action alleging its testosterone drug AndroGel caused cardiovascular problems.
AMAG Pharmaceuticals has big ambitions for its women’s health business, so it’s snapped up the rights to a new med, Intrarosa, to beef up that portfolio. And it’s bringing on 150 new reps to detail the med.
Manufacturing problems have led to the recall of the thyroid-hormone replacement therapy Synthroidfor the second time in 6 months.